Institute for Cancer Genetics and Informatics, Oslo University Hospital’s Post

🔬 Microwave Ablation vs. Radiofrequency Ablation in Liver Cancer: 2021 Systematic Review and Meta-Analysis 🔬 Significant systematic review and meta-analysis provided valuable insights into the comparison between Microwave Ablation (MWA) and Radiofrequency Ablation (RFA) for treating liver cancer. Key Results: ▷No significant difference in overall local tumor progression (LTP) between MWA and RFA. ▷Subgroup Analysis: MWA showed a statistically significant reduction in LTP for hepatocellular carcinoma (HCC) patients. ▷No differences in complete ablation, intrahepatic distant recurrence, complications, or tumor size. 🔍 Conclusion: MWA demonstrated promising results, especially in reducing LTP for HCC patients, indicating its potential as the preferred ablation method for these patients. 📚 Authors: Antonios E Spiliotis, Gereon Gäbelein, Sebastian Holländer, Philipp-Robert Scherber, Matthias Glanemann, Prof Bijendra Patel https://lnkd.in/gpAcFvtR #LiverCancer #MicrowaveAblation #MedicalResearch #CME #PhysicianInsights #Oncology #CancerTreatment

This cohort study assesses the magnitude of cancer registration delays and their estimated affects on the NordICC trial results assessing the long-term effects of screening colonoscopy in preventing colorectal cancer. https://ja.ma/3ZJ44dp

ESMO recommendations for the use of NGS for patients with advanced cancer which includes the use of tumour NGS to detect tumour-agnostic alterations in patients with metastatic cancers where access to matched therapies is available 🧬 #cancer #genomics #cancergenomics #NGS #stratifiedmedicine 👇🏼 https://lnkd.in/eupyGEbs

Clarity’s abstract titled “Treatment of metastatic castrate-resistant prostate cancer patient with two cycles of 67Cu-SAR-bisPSMA (8GBq) leads to undetectable PSA level: A case report” was selected and presented this week at the 34th Annual International Prostate Cancer Update (IPCU) in Vail, Colorado during the video abstract portion of Session 7: Advanced Prostate Cancer.   In the video abstract, Dr Luke Nordquist MD FACP shared his experience treating the first patient ever with two cycles of 8GBq of 67Cu-SAR-bisPSMA. After receiving the two doses, the patient had a drop in PSA to undetectable levels, undetectable disease using PET and a near complete response to treatment according to RECIST assessment at the time of imaging. The patient experienced only a mild dry mouth, altered taste (both improved) and moderate fatigue (resolved).   Watch the video abstract below to learn more about this patient case report. For more information about the SECuRE trial, visit ClinicalTrials.gov (NCT04868604). The safety and efficacy of the products outlined in this presentation are investigational and the respective data have not been assessed by any health authorities.

Contralateral Breast Cancer Treatment With Germline Mutation Carriers https://ow.ly/rjho50Rlxyu

NCI ARTNet a program supported by the Division of Cancer Biology and NCI Division of Cancer Treatment and Diagnosis, focuses on the mechanisms of acquired resistance to #CancerTherapies and disease recurrence. https://lnkd.in/eBcw6zVe

Our recent book chapter, titled "Functionalized Liposomes and Niosomes for Cancer Therapy," has been published by #Elsevier. I co-authored this chapter with my esteemed colleagues Maryam Yavari, Negar Nasri, and Dr. Atefeh Zarepour under the supervision of Prof. Ali Zarrabi and Dr. Ebrahim Mostafavi, PhD. This chapter, which is Chapter 16 of the book "Functionalized Nanomaterials for Cancer Research," delves into the fascinating world of lipid-based nanocarriers and their potential in cancer therapy. Liposomes and niosomes are lipid-based nanocarriers that have attracted significant attention due to their unique structural features resembling cellular membranes. Our book chapter aims to provide an in-depth exploration of functionalized liposomal and niosomal therapeutic nanoparticles for cancer treatment. We begin by discussing the distinct structural features of liposomes and niosomes, along with their diverse preparation methods. Furthermore, we delve into different generations of liposomes and niosomes, shedding light on the various types of functionalization that can greatly impact their stability, loading capacity, and bioavailability within targeted cancer tissues. If you're interested in learning more about the cutting-edge developments in liposomal and niosomal therapies for cancer, this book chapter is definitely a must-read!  The links to the book and book chapter are provided below: The book chapter: https://lnkd.in/dySGemUN  The book: https://lnkd.in/dyMPCUA3 #CancerResearch #Nanomedicine #TherapeuticNanoparticles #Liposomes #Niosomes #TargetedTherapy

Contralateral Breast Cancer Treatment With Germline Mutation Carriers https://ow.ly/YxiV50Rlxyw

#ARTEMISPC #MRD #clinicaltrial in #patients w/ resectable & unresectable #pancreaticcancer Invitae #NationalCancerCenterHospitalEast #TrialsinProgress #GI24 @ American Society of Clinical Oncology (ASCO) https://lnkd.in/gVW5BFh9 https://lnkd.in/gJNSmdWS Video Journal of Oncology (VJOncology) Pancreatic Cancer Action Network Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC)

The prostate cancer diagnosis process can feel overwhelming for a variety of reasons, including inconclusive test results. Join OBD and the Prostate Forum of Orange County for a virtual fireside chat with board-certified pathologist Dr. Heaton to get your questions answered and learn more about our 94% accurate prostate screening blood test. 📅 Date & Time: February 27, 2024, at 5pm PT/8pm ET 🌐 Zoom link: mypse.co/prostateforum 🔬 Topic: Advancing Precision Medicine with EpiSwitch PSE Prostate Cancer Screening Test 👨⚕️ Discover the revolutionary EpiSwitch Prostate Screening test (PSE) with Dr. Heaton. This advanced test confirms the presence or absence of prostate cancer, helping to guide doctors and patients in decision-making for biopsies or continued monitoring. Don't miss this opportunity to empower yourself with crucial information! Learn more about the PSE test at 94percent.com. 👉 Stick around after for the Advanced/Recurring Support Group hosted by Dr. Charles Metzger (retired) and Ira Kaget. Engage in informative conversations about advanced prostate cancer. Learn more: https://lnkd.in/giw5q6uZ. 🤝 Organized by The Prostate Forum of Orange County (PFOC), supporting anyone affected by Prostate Cancer. Your participation and support are crucial to their mission. For more information, visit prostateforum.org. #ProstateCancer #ProstateCancerAwareness